Pittsburgh, PA, United States of America

Daniel Long

This inventor holds 2 USPTO granted patents. Top assignee: University of Pittsburgh. Active years: 2022-2024.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2022-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Daniel Long in Therapeutic Proteins

Introduction

Daniel Long is an accomplished inventor based in Pittsburgh, PA (US). He has made significant contributions to the field of therapeutic proteins, holding 2 patents that focus on innovative compositions for medical applications. His work is particularly relevant in the areas of wound healing and myocardial infarction treatment.

Latest Patents

Daniel Long's latest patents include groundbreaking compositions that utilize a coacervate of polycationic and polyanionic polymers combined with platelet-rich plasma and serum. These compositions are designed to enhance wound healing. Additionally, he has developed a hydrogel that incorporates TIMP-3 and a complex of various proteins, which is aimed at treating myocardial infarction. These innovations demonstrate his commitment to advancing medical science through effective therapeutic solutions.

Career Highlights

Long is affiliated with the University of Pittsburgh, where he continues to push the boundaries of research in therapeutic applications. His work has garnered attention for its potential to improve patient outcomes in critical medical situations.

Collaborations

Daniel Long collaborates with notable colleagues such as Eric M Jeffries and Yadong Wang. Their combined expertise contributes to the advancement of research in the field of therapeutic proteins.

Conclusion

Daniel Long's innovative work in the realm of therapeutic proteins showcases his dedication to improving healthcare solutions. His patents reflect a significant step forward in medical technology, particularly in wound healing and cardiac care.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…